Zaman, Farzana Y. http://orcid.org/0000-0002-2095-0850
Orchard, Suzanne G. http://orcid.org/0000-0003-0211-3183
Haydon, Andrew http://orcid.org/0000-0002-4631-5855
Zalcberg, John R.
Article History
Received: 28 January 2022
Revised: 27 May 2022
Accepted: 1 June 2022
First Online: 28 June 2022
Competing interests
: FYZ, SO and AH have no competing interests. JZ has a leadership role at the ICON Group; owns stock in Biomarin, Opthea, Amarin Corporation, Concert Pharmaceuticals, Frequency Therapeutics, Gilead Sciences, Madrigal Pharmaceuticals, UniQure, Zogenix, Orphazyme, Moderna Therapeutics, Twist Bioscience and Novavax; has received honoraria from Specialised Therapeutics, Merck Serono, Targovax, Halozyme, Gilead Sciences, and Deciphera; serves in an advisory/consultancy role for Merck Serono, Targovax, Merck Sharp and Dohme, Halozyme, Lipotek, Specialized Therapeutics, CEND Therapeutics, Deciphera, Revolution Medicine, FivePHusion, Genor Biopharma, Globe Health Institute and Novotech; and his institution has received research funding from Merck Serono, Bristol-Myers Squibb, AstraZeneca, Pfizer, IQvia, Mylan, Ipsen, Eisai, Medtronic, and MSD Oncology; and has received travel, accommodations, expenses from Merck Serono, AstraZeneca, Merck Sharp and Dohme, Deciphera and Sanofi.
: This work does not require any ethics approval or participating consent.
: Not applicable.